Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models
Aims Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers...
Gespeichert in:
Veröffentlicht in: | Neuropathology and applied neurobiology 2021-02, Vol.47 (1), p.43-60 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 60 |
---|---|
container_issue | 1 |
container_start_page | 43 |
container_title | Neuropathology and applied neurobiology |
container_volume | 47 |
creator | La Vitola, P. Balducci, C. Baroni, M. Artioli, L. Santamaria, G. Castiglioni, M. Cerovic, M. Colombo, L. Caldinelli, L. Pollegioni, L. Forloni, G. |
description | Aims
Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking.
Methods
To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice.
Results
Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice.
Conclusions
The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies. |
doi_str_mv | 10.1111/nan.12644 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2426177441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426177441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</originalsourceid><addsrcrecordid>eNp10M0uBTEYxvFGCMfHwg3IJBZYDO20pzNdnoivRLBgPanOW0qnPdqZMDuX4FbciItwJcrBQqKbbn75582D0DrBuyS9PSfdLik4Y3NoRCgf54UQeB6NMMXjnFSML6HlGO8wxuOSi0W0RAsuuBBihJoLCGZ6C0HazDhtZdvKzniXwZNUEK5lBzF7e31_fomD65UF47LOPxlluiGTrskc9MFPZXfrrb8ZUiO7kOHeuOjdVsxa34CNq2hBSxth7ftfQVeHB5f7x_np-dHJ_uQ0V3RMWa6plkAV1pJXSjUCcCMYrxhJZ5eKcqwrSgTHApgsm5JWVQFMKK2pLBhhiq6g7Vl3GvxDD7GrWxMVWCsd-D7WBSs4KUvGSKKbf-id74NL1yVVFZRwQUVSOzOlgo8xgK6nwbQyDDXB9ef0dZq-_po-2Y3vYn_dQvMrf7ZOYG8GHo2F4f9SfTY5myU_AKmhkAE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482316939</pqid></control><display><type>article</type><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</creator><creatorcontrib>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</creatorcontrib><description>Aims
Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking.
Methods
To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice.
Results
Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice.
Conclusions
The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</description><identifier>ISSN: 0305-1846</identifier><identifier>EISSN: 1365-2990</identifier><identifier>DOI: 10.1111/nan.12644</identifier><identifier>PMID: 32696999</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>alpha-Synuclein - metabolism ; alpha-Synuclein - pharmacology ; Animal models ; Animals ; Astrocytes ; Astrocytes - metabolism ; Axons ; Cognitive ability ; Disease Models, Animal ; Environmental factors ; Glial cells ; Inflammation ; Inflammation - pathology ; Lewy bodies ; Lipopolysaccharides ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microglia ; Microglia - pathology ; Movement disorders ; Nerve Degeneration - drug therapy ; Nerve Degeneration - pathology ; Nervous System Diseases - pathology ; Neurodegenerative diseases ; neuroinflammation ; Neurotoxicity ; nonmotor deficits ; oligomeropathies ; Parkinson Disease - metabolism ; Parkinson Disease - pathology ; Parkinson's disease ; Phenotypes ; Substantia Nigra - drug effects ; Substantia Nigra - pathology ; Synuclein ; Transgenic mice ; α‐synuclein oligomers</subject><ispartof>Neuropathology and applied neurobiology, 2021-02, Vol.47 (1), p.43-60</ispartof><rights>2020 British Neuropathological Society</rights><rights>2020 British Neuropathological Society.</rights><rights>Copyright © 2021 British Neuropathological Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</citedby><cites>FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</cites><orcidid>0000-0001-5374-3914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnan.12644$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnan.12644$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32696999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>La Vitola, P.</creatorcontrib><creatorcontrib>Balducci, C.</creatorcontrib><creatorcontrib>Baroni, M.</creatorcontrib><creatorcontrib>Artioli, L.</creatorcontrib><creatorcontrib>Santamaria, G.</creatorcontrib><creatorcontrib>Castiglioni, M.</creatorcontrib><creatorcontrib>Cerovic, M.</creatorcontrib><creatorcontrib>Colombo, L.</creatorcontrib><creatorcontrib>Caldinelli, L.</creatorcontrib><creatorcontrib>Pollegioni, L.</creatorcontrib><creatorcontrib>Forloni, G.</creatorcontrib><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><title>Neuropathology and applied neurobiology</title><addtitle>Neuropathol Appl Neurobiol</addtitle><description>Aims
Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking.
Methods
To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice.
Results
Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice.
Conclusions
The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</description><subject>alpha-Synuclein - metabolism</subject><subject>alpha-Synuclein - pharmacology</subject><subject>Animal models</subject><subject>Animals</subject><subject>Astrocytes</subject><subject>Astrocytes - metabolism</subject><subject>Axons</subject><subject>Cognitive ability</subject><subject>Disease Models, Animal</subject><subject>Environmental factors</subject><subject>Glial cells</subject><subject>Inflammation</subject><subject>Inflammation - pathology</subject><subject>Lewy bodies</subject><subject>Lipopolysaccharides</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Microglia</subject><subject>Microglia - pathology</subject><subject>Movement disorders</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - pathology</subject><subject>Nervous System Diseases - pathology</subject><subject>Neurodegenerative diseases</subject><subject>neuroinflammation</subject><subject>Neurotoxicity</subject><subject>nonmotor deficits</subject><subject>oligomeropathies</subject><subject>Parkinson Disease - metabolism</subject><subject>Parkinson Disease - pathology</subject><subject>Parkinson's disease</subject><subject>Phenotypes</subject><subject>Substantia Nigra - drug effects</subject><subject>Substantia Nigra - pathology</subject><subject>Synuclein</subject><subject>Transgenic mice</subject><subject>α‐synuclein oligomers</subject><issn>0305-1846</issn><issn>1365-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M0uBTEYxvFGCMfHwg3IJBZYDO20pzNdnoivRLBgPanOW0qnPdqZMDuX4FbciItwJcrBQqKbbn75582D0DrBuyS9PSfdLik4Y3NoRCgf54UQeB6NMMXjnFSML6HlGO8wxuOSi0W0RAsuuBBihJoLCGZ6C0HazDhtZdvKzniXwZNUEK5lBzF7e31_fomD65UF47LOPxlluiGTrskc9MFPZXfrrb8ZUiO7kOHeuOjdVsxa34CNq2hBSxth7ftfQVeHB5f7x_np-dHJ_uQ0V3RMWa6plkAV1pJXSjUCcCMYrxhJZ5eKcqwrSgTHApgsm5JWVQFMKK2pLBhhiq6g7Vl3GvxDD7GrWxMVWCsd-D7WBSs4KUvGSKKbf-id74NL1yVVFZRwQUVSOzOlgo8xgK6nwbQyDDXB9ef0dZq-_po-2Y3vYn_dQvMrf7ZOYG8GHo2F4f9SfTY5myU_AKmhkAE</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>La Vitola, P.</creator><creator>Balducci, C.</creator><creator>Baroni, M.</creator><creator>Artioli, L.</creator><creator>Santamaria, G.</creator><creator>Castiglioni, M.</creator><creator>Cerovic, M.</creator><creator>Colombo, L.</creator><creator>Caldinelli, L.</creator><creator>Pollegioni, L.</creator><creator>Forloni, G.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5374-3914</orcidid></search><sort><creationdate>202102</creationdate><title>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</title><author>La Vitola, P. ; Balducci, C. ; Baroni, M. ; Artioli, L. ; Santamaria, G. ; Castiglioni, M. ; Cerovic, M. ; Colombo, L. ; Caldinelli, L. ; Pollegioni, L. ; Forloni, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-f3fae3c0fa68ccd9e0d9468410577c360f8319609e4a7d73882e49cff3a2414c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>alpha-Synuclein - metabolism</topic><topic>alpha-Synuclein - pharmacology</topic><topic>Animal models</topic><topic>Animals</topic><topic>Astrocytes</topic><topic>Astrocytes - metabolism</topic><topic>Axons</topic><topic>Cognitive ability</topic><topic>Disease Models, Animal</topic><topic>Environmental factors</topic><topic>Glial cells</topic><topic>Inflammation</topic><topic>Inflammation - pathology</topic><topic>Lewy bodies</topic><topic>Lipopolysaccharides</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Microglia</topic><topic>Microglia - pathology</topic><topic>Movement disorders</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - pathology</topic><topic>Nervous System Diseases - pathology</topic><topic>Neurodegenerative diseases</topic><topic>neuroinflammation</topic><topic>Neurotoxicity</topic><topic>nonmotor deficits</topic><topic>oligomeropathies</topic><topic>Parkinson Disease - metabolism</topic><topic>Parkinson Disease - pathology</topic><topic>Parkinson's disease</topic><topic>Phenotypes</topic><topic>Substantia Nigra - drug effects</topic><topic>Substantia Nigra - pathology</topic><topic>Synuclein</topic><topic>Transgenic mice</topic><topic>α‐synuclein oligomers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>La Vitola, P.</creatorcontrib><creatorcontrib>Balducci, C.</creatorcontrib><creatorcontrib>Baroni, M.</creatorcontrib><creatorcontrib>Artioli, L.</creatorcontrib><creatorcontrib>Santamaria, G.</creatorcontrib><creatorcontrib>Castiglioni, M.</creatorcontrib><creatorcontrib>Cerovic, M.</creatorcontrib><creatorcontrib>Colombo, L.</creatorcontrib><creatorcontrib>Caldinelli, L.</creatorcontrib><creatorcontrib>Pollegioni, L.</creatorcontrib><creatorcontrib>Forloni, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropathology and applied neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>La Vitola, P.</au><au>Balducci, C.</au><au>Baroni, M.</au><au>Artioli, L.</au><au>Santamaria, G.</au><au>Castiglioni, M.</au><au>Cerovic, M.</au><au>Colombo, L.</au><au>Caldinelli, L.</au><au>Pollegioni, L.</au><au>Forloni, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models</atitle><jtitle>Neuropathology and applied neurobiology</jtitle><addtitle>Neuropathol Appl Neurobiol</addtitle><date>2021-02</date><risdate>2021</risdate><volume>47</volume><issue>1</issue><spage>43</spage><epage>60</epage><pages>43-60</pages><issn>0305-1846</issn><eissn>1365-2990</eissn><abstract>Aims
Parkinson’s disease and related disorders are devastating neurodegenerative pathologies. Since α‐synuclein was identified as a main component of Lewy bodies and neurites, efforts have been made to clarify the pathogenic mechanisms of α‐synuclein's detrimental effects. α‐synuclein oligomers are the most harmful species and may recruit and activate glial cells. Inflammation is emerging as a bridge between genetic susceptibility and environmental factors co‐fostering Parkinson’s disease. However, direct evidence linking inflammation to the harmful activities of α‐synuclein oligomers or to the Parkinson’s disease behavioural phenotype is lacking.
Methods
To clarify whether neuroinflammation influences Parkinson’s disease pathogenesis, we developed: (i) a ‘double‐hit’ approach in C57BL/6 naive mice where peripherally administered lipopolysaccharides were followed by intracerebroventricular injection of an inactive oligomer dose; (ii) a transgenic ‘double‐hit’ model where lipopolysaccharides were given to A53T α‐synuclein transgenic Parkinson’s disease mice.
Results
Lipopolysaccharides induced a long‐lasting neuroinflammatory response which facilitated the detrimental cognitive activities of oligomers. LPS‐activated microglia and astrocytes responded differently to the oligomers with microglia activating further and acquiring a pro‐inflammatory M1 phenotype, while astrocytes atrophied. In the transgenic ‘double‐hit’ A53T mouse model, lipopolysaccharides aggravated cognitive deficits and increased microgliosis. Again, astrocytes responded differently to the double challenge. These findings indicate that peripherally induced neuroinflammation potentiates the α‐synuclein oligomer’s actions and aggravates cognitive deficits in A53T mice.
Conclusions
The fine management of both peripheral and central inflammation may offer a promising therapeutic approach to prevent or slow down some behavioural aspects in α‐synucleinopathies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32696999</pmid><doi>10.1111/nan.12644</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0001-5374-3914</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-1846 |
ispartof | Neuropathology and applied neurobiology, 2021-02, Vol.47 (1), p.43-60 |
issn | 0305-1846 1365-2990 |
language | eng |
recordid | cdi_proquest_miscellaneous_2426177441 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | alpha-Synuclein - metabolism alpha-Synuclein - pharmacology Animal models Animals Astrocytes Astrocytes - metabolism Axons Cognitive ability Disease Models, Animal Environmental factors Glial cells Inflammation Inflammation - pathology Lewy bodies Lipopolysaccharides Mice Mice, Inbred C57BL Mice, Transgenic Microglia Microglia - pathology Movement disorders Nerve Degeneration - drug therapy Nerve Degeneration - pathology Nervous System Diseases - pathology Neurodegenerative diseases neuroinflammation Neurotoxicity nonmotor deficits oligomeropathies Parkinson Disease - metabolism Parkinson Disease - pathology Parkinson's disease Phenotypes Substantia Nigra - drug effects Substantia Nigra - pathology Synuclein Transgenic mice α‐synuclein oligomers |
title | Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T11%3A14%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20inflammation%20exacerbates%20%CE%B1%E2%80%90synuclein%20toxicity%20and%20neuropathology%20in%20Parkinson's%20models&rft.jtitle=Neuropathology%20and%20applied%20neurobiology&rft.au=La%20Vitola,%20P.&rft.date=2021-02&rft.volume=47&rft.issue=1&rft.spage=43&rft.epage=60&rft.pages=43-60&rft.issn=0305-1846&rft.eissn=1365-2990&rft_id=info:doi/10.1111/nan.12644&rft_dat=%3Cproquest_cross%3E2426177441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2482316939&rft_id=info:pmid/32696999&rfr_iscdi=true |